MEA Erythropoietin Drugs Market

Middle East & Africa Erythropoietin Drugs Market Size (2024 to 2029)

As per the research report, the MEA Erythropoietin Drugs Market Size is valued at USD 0.92 billion in 2024 and expected to grow at a CAGR of 9.65%, reaching USD 1.46 billion by the end of 2029 during the forecast period 2024 to 2029.

The increasing prevalence of anemic diseases induced by end-stage renal disease treatment, chemotherapy, and antiretroviral therapy (ART) is the growth of the MEA erythropoietin drug market. In addition, recently, there have been increasing incidences of end-stage renal disease (dialysis), which has increased the demand for the market.

Cellular tests are easy to develop, cost-effective, and require less time for approval than biological tests, driving the growth of the MEA EPO market during the projected period. Major companies are focusing on extensive R&D initiatives for developing newer regimes, formulating better drugs with lesser side effects, and therapeutic applications for existing EPO drugs.

The high success rate of EPO drugs for chemotherapy-induced anemia is one of the drivers of market growth, but the major drawback is the EPO drug-induced side effects when used for long-term durations. As a result, many biopharmaceutical companies are focusing on another form of anemia induced by ART (in patients with HIV infection) to help patient needs. In addition, EPO drugs have other beneficial cellular protective effects, including anti-ischemic, regenerative, and anti-oncogenic impacts on various organs.

In addition, growing marketing trends for erythropoietin-based stem cell therapies, available discounts, favorable government regulations, and increasing awareness of the benefits of erythropoietin-based drug therapies are stimulating the MEA market growth rate for the forecast period.

However, the high cost of manufacturing erythropoietin drugs, especially in developing countries, can drag on its growth. Moreover, factors such as side effects associated with EPO drugs which include high blood pressure, iron deficiency, and flu-like symptoms, as well as the longer duration of EPO treatment (4-6 weeks), are limiting the growth of the MEA EPO drugs market.

This research report on the MEA Erythropoietin Drugs Market has been segmented and sub-segmented into the following categories.

Middle East & Africa Erythropoietin Drugs Market Analysis Size By Product

• Epoetin-alpha
• Epoetin-beta
• Darbepoetin-alfa
• Others

Middle East & Africa Erythropoietin Drugs Market Analysis By Application

• Cancer
• Hematology
• Renal Diseases
• Neurology

Middle East & Africa Erythropoietin Drugs Market Analysis By Drug Class

• Biologics
• Biosimilar

Middle East & Africa Erythropoietin Drugs Market Analysis By Country

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the MEA EPO drugs market will have lucrative growth opportunities in upcoming years. And this region holds the largest share of the biopharmaceutical industry due to the development of newer drugs by the major manufacturers in these regions.

The UAE Erythropoietin drugs market is predicted to rise significantly due to the costs of manufacturing and distribution of the EPO drugs being lesser in the Middle East due to the presence of cheap labor during the forecast period.

The Saudi Arabia Erythropoietin drugs market is projected to witness a decent CAGR due to the better reimbursement policies and increased healthcare awareness that helps generate good revenues.

The South African Erythropoietin drugs Market is predicted to witness the highest CAGR due to the factors such as increasing rates of chronic diseases and the increased investment in discovery activities drugs have led regions in MEA to have a demand for erythropoietin drugs.

Many regions of Africa are also expected to have a good demand for EPO drugs due to their large senior population. But the supply is expected to be lower due to a lack of funds and the long production period.

KEY MARKET PLAYERS

Notable companies dominating the MEA Erythropoietin Drugs Market profiled in the report are Johnson & Johnson, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Celltrion, Inc, Amgen, Inc., F. Hoffmann-La Roche Ltd., LG Life Sciences Ltd., Teva Pharmaceutical Industries Ltd., Biocon Limited and Intas Pharmaceuticals Ltd.,